SCM
GYRE icon

Sterling Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Sterling Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$411 Hold
59
– – ﹤0.01% 3168
2025
Q4 		$417 Buy
59
+37
+168% +$286 ﹤0.01% 3203
2025
Q3 		$164 Sell
22
-11
-33% -$84 ﹤0.01% 3222
2025
Q2 		$243 Sell
33
-73
-69% -$637 ﹤0.01% 3225
2025
Q1 		$818 Sell
106
-110
-51% -$1.21K ﹤0.01% 2877
2024
Q4 		$2.61K Buy
216
+195
+929% +$2.5K ﹤0.01% 2703
2024
Q3 		$263 Buy
+21
New +$271 ﹤0.01% 3063

Other funds holding GYRE

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Sterling Capital Management's GYRE Position: Q1 2026 in Review

Sterling Capital Management held its Gyre Therapeutics (GYRE) position steady in Q1 2026 at 59 shares worth $411. The position accounts for ﹤0.01% of the portfolio, ranked #3168.

Sterling Capital Management first reported a position in GYRE in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.61K in Q4 2024. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

  • Sterling Capital Management held 59 shares of Gyre Therapeutics worth $411 as of Q1 2026.
  • Sterling Capital Management left its Gyre Therapeutics share count unchanged in Q1 2026.
  • Gyre Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #3168 holding.
  • Sterling Capital Management first reported a position in Gyre Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Gyre Therapeutics position peaked at $2.61K in Q4 2024.
  • 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.